Share on StockTwits

Advisory Board (NASDAQ:ABCO) President David L. Felsenthal sold 6,437 shares of the company’s stock on the open market in a transaction that occurred on Thursday, January 16th. The stock was sold at an average price of $60.24, for a total transaction of $387,764.88. Following the completion of the sale, the president now directly owns 17,275 shares in the company, valued at approximately $1,040,646. The sale was disclosed in a document filed with the SEC, which is available at this link.

Advisory Board (NASDAQ:ABCO) traded up 0.51% on Friday, hitting $61.14. The stock had a trading volume of 90,780 shares. Advisory Board has a 52-week low of $44.20 and a 52-week high of $70.55. The stock has a 50-day moving average of $61.99 and a 200-day moving average of $60.5. The company has a market cap of $2.204 billion and a P/E ratio of 93.58.

Advisory Board (NASDAQ:ABCO) last issued its quarterly earnings data on Monday, November 4th. The company reported $0.31 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.29 by $0.02. The company had revenue of $128.30 million for the quarter, compared to the consensus estimate of $127.96 million. During the same quarter in the prior year, the company posted $0.31 earnings per share. The company’s quarterly revenue was up 15.8% on a year-over-year basis. Analysts expect that Advisory Board will post $1.24 EPS for the current fiscal year.

A number of analysts have recently weighed in on ABCO shares. Analysts at Raymond James downgraded shares of Advisory Board from an “outperform” rating to a “market perform” rating in a research note to investors on Wednesday, November 6th. They now have a $66.00 price target on the stock. They noted that the move was a valuation call. Analysts at Stifel Nicolaus raised their price target on shares of Advisory Board from $68.00 to $75.00 in a research note to investors on Tuesday, November 5th. They now have a “buy” rating on the stock. Two research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $65.17.

The Advisory Board Company provides best practices research and analysis, software tools, and management and advisory services to the health care and education industries.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.